Universidade Federal de Santa Maria, Departamento de Patologia, Avenida Roraima, 1000, Prédio 20, 97105-900 Santa Maria, RS, Brazil.
Universidade Federal de Santa Maria, Departamento de Estomatologia, Avenida Roraima, 1000, Prédio 26; 97105-900 Santa Maria, RS, Brazil.
An Acad Bras Cienc. 2024 Aug 26;96(3):e20230462. doi: 10.1590/0001-3765202420230462. eCollection 2024.
This observational study aimed retrospectively assess the impact of the COVID-19 pandemic on the head and neck squamous cell carcinoma (HNSCC) diagnosis and severity of the disease in southern Brazil. All new cases diagnosed with HNSCC from March 11, 2019 to March 10, 2020 (pre-COVID-19) and from March 11, 2020 to March 10, 2021 (COVID-19) were included. The data collected were: date of the histopathological diagnosis, sociodemographic data, place of residence, data related to the tumor (location of the primary tumor, lymph node involvement, distant metastasis and TNM clinical staging), time elapsed between the diagnosis and treatment initiation. There was no significant difference in the number of new diagnoses in the COVID-19 group (n=45) compared to the pre-COVID-19 group (n=47). There was also no statistical difference regarding patients' sociodemographic profile, time between diagnosis and treatment, and overall TNM staging. However, the clinical N classification was more severe in the COVID-19 group (p=0.021). Patients diagnosed during the COVID-19 pandemic were 4.05 times more likely to have the N-stage more advanced (95% CI:1.62 - 10.12). Although there was no reduction in the number of new diagnosis of HNSCC during COVID-19 pandemic, the diagnosed cases showed lymph node metastasis in more advanced stages.
这项观察性研究旨在回顾性评估 COVID-19 大流行对巴西南部头颈部鳞状细胞癌(HNSCC)诊断和疾病严重程度的影响。所有 2019 年 3 月 11 日至 2020 年 3 月 10 日(COVID-19 前)和 2020 年 3 月 11 日至 2021 年 3 月 10 日(COVID-19 期间)诊断为 HNSCC 的新病例均被纳入研究。收集的数据包括:组织病理学诊断日期、社会人口统计学数据、居住地点、与肿瘤相关的数据(原发肿瘤位置、淋巴结受累、远处转移和 TNM 临床分期)、诊断与治疗开始之间的时间间隔。COVID-19 组(n=45)与 COVID-19 前组(n=47)的新诊断数量无显著差异。患者的社会人口统计学特征、诊断与治疗之间的时间以及总体 TNM 分期也无统计学差异。然而,COVID-19 组的临床 N 分类更为严重(p=0.021)。在 COVID-19 大流行期间诊断的患者发生更晚期 N 期的可能性是 COVID-19 前组的 4.05 倍(95%CI:1.62 - 10.12)。尽管 COVID-19 大流行期间 HNSCC 的新诊断数量没有减少,但诊断出的病例显示淋巴结转移处于更晚期。